NKTR (Nektar Therapeutics)
Insider Trading Activity
Every open-market purchase and sale reported by NKTR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-20 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| 2026-08-20 | HOWARD W ROBIN | President & CEO | Sell | — | — |
| 2026-07-24 | Jonathan Zalevsky | Chief R&D Officer | A | — | — |
| 2026-07-24 | HOWARD W ROBIN | President & CEO | A | — | — |
| 2026-07-02 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| 2026-06-18 | HOWARD W ROBIN | President & CEO | Sell | — | — |
| 2026-06-17 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| 2026-05-21 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| 2026-05-21 | HOWARD W ROBIN | President & CEO | Sell | — | — |
| 2026-02-20 | HOWARD W ROBIN | President & CEO | Sell | — | — |
| 2026-02-20 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| 2026-01-22 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| 2025-12-23 | Jonathan Zalevsky | Chief R&D Officer | A | — | — |
| 2025-12-23 | HOWARD W ROBIN | President & CEO | A | — | — |
| 2025-11-25 | Mark Andrew Wilson | Chief Legal Officer | MIXED | — | — |
| 2025-11-25 | Jonathan Zalevsky | Chief R&D Officer | MIXED | — | — |
| 2025-11-25 | HOWARD W ROBIN | President & CEO | MIXED | — | — |
| 2025-10-01 | ROY A WHITFIELD | Director | A | — | — |
| 2025-10-01 | ROBERT CHESS | Director | A | — | — |
| 2025-10-01 | Diana Brainard | Director | A | — | — |
| 2025-10-01 | Jeffrey Robert Ajer | Director | A | — | — |
| 2025-10-01 | R SCOTT GREER | Director | A | — | — |
| 2025-09-11 | HOWARD W ROBIN | President & CEO | Sell | — | — |
| 2025-09-08 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| 2025-09-08 | HOWARD W ROBIN | President & CEO | Sell | — | — |
| 2025-09-04 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| 2025-09-04 | HOWARD W ROBIN | President & CEO | Sell | — | — |
| 2025-08-21 | Mark Andrew Wilson | Chief Legal Officer | Sell | — | — |
| 2025-08-21 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| 2025-08-21 | HOWARD W ROBIN | President & CEO | Sell | — | — |
| 2025-05-21 | Mark Andrew Wilson | Chief Legal Officer | Sell | — | — |
| 2025-05-21 | HOWARD W ROBIN | President & CEO | Sell | — | — |
| 2025-05-21 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| 2025-02-21 | Mark Andrew Wilson | Chief Legal Officer | Sell | — | — |
| 2025-02-21 | HOWARD W ROBIN | President & CEO | Sell | — | — |
| 2025-02-21 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| 2024-12-26 | Mark Andrew Wilson | Chief Legal Officer | Sell | — | — |
| 2024-12-20 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| 2024-12-19 | HOWARD W ROBIN | President & CEO | Sell | — | — |
| 2024-12-17 | HOWARD W ROBIN | President & CEO | A | — | — |
| 2024-12-17 | Jonathan Zalevsky | Chief R&D Officer | A | — | — |
| 2024-12-17 | Mark Andrew Wilson | Chief Legal Officer | A | — | — |
| 2024-11-20 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| 2024-11-20 | Mark Andrew Wilson | Chief Legal Officer | Sell | — | — |
| 2024-11-20 | HOWARD W ROBIN | President & CEO | Sell | — | — |
| 2024-08-20 | Mark Andrew Wilson | Chief Legal Officer | Sell | — | — |
| 2024-08-20 | HOWARD W ROBIN | President & CEO | Sell | — | — |
| 2024-08-20 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| 2024-06-14 | ROBERT CHESS | Director | Sell | — | — |
| 2024-05-20 | Jonathan Zalevsky | Chief R&D Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,222,933 | — |
| — | President & CEO | 54,655 | — |
| — | Chief Legal Officer | 21,585 | — |
| — | Chief Scientific Officer | 20,976 | — |
| — | Chief Financial Officer | 20,900 | — |
| — | SVP, COO & CFO | 20,860 | — |
| — | Director | 20,238 | — |
| — | Director | 17,850 | — |
| — | Director | 17,158 | — |
| — | Director | 15,426 | — |
| — | SVP & Chief Commercial Officer | 14,881 | — |
| — | SVP & Chief Operating Officer | 10,851 | — |
| — | Chief R&D Officer | 9,570 | — |
| — | SVP & Chief Scientific Officer | 7,178 | — |
| — | SVP Pharma Dev & Mfg Ops | 6,313 | — |
| — | Director | 5,467 | — |
| — | SVP & Chief Medical Officer | 4,105 | — |
| — | Director | 3,183 | — |
| — | Director | 3,017 | — |
| — | Chief Executive Officer | 2,808 | — |
| — | Director | 2,558 | — |
| — | Director | 2,558 | — |
| — | Director | 2,387 | — |
| — | Director | 2,342 | — |
| — | Director | 2,277 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NKTR quote page; the site-wide leaderboard is on the insider transactions hub.